drugset / Trial / NCT00126191
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Phase 2
Terminated
10 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to learn more about how well a chemotherapy regime including rituximab works in treating patients with Burkitt or atypical Burkitt lymphoma.
Timeline
- Start
- 2005-07
- Primary completion
- 2009-12
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 275 mg/m2 | — |
| Subject | Cyclophosphamide | Other / unclassified | 800 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 50 mg | Intrathecal |
| Subject | Cytarabine | Small molecule | 2 g | Intrathecal |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Subject | Etoposide | Small molecule | 60 unknown | — |
| Subject | Ifosfamide | Small molecule | 1500 mg/m2 | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Methotrexate | Small molecule | 12 mg | Intrathecal |
| Subject | Methotrexate | Small molecule | 50 mg | Intrathecal |
| Subject | Methotrexate | Small molecule | 3000 mg/m2 | Intrathecal |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |